Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with Nonvalvular Atrial fibrillation

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 2, 2015, Pages 146-153

  Senoo, Keitaro ^a   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

atrial fibrillation; clinical trial; non VKA oral anticoagulants; stroke prevention; vitamin K antagonist

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; KIDNEY FAILURE; NONVALVULAR ATRIAL FIBRILLATION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; FEMALE; HEMORRHAGE; MALE; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; VITAMIN K;

EID: 84923925310     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1544156     Document Type: Article

References (36)

1. Go A. S., Hylek E. M., Phillips K. A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA: 2001; 285 18 2370 2375
2. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest: 2005; 127 1 415 416
3. You J. J., Singer D. E., Howard P. A., et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e531S e575S
4. De Caterina R., Husted S., Wallentin L., et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost: 2013; 110 6 1087 1107
5. Le Heuzey J. Y., Ammentorp B., Darius H., et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost: 2014; 111 5 833 841
6. Lip G. Y., Laroche C., Dan G. A., et al. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Am J Med: 2014; 127 6 519 29.e1
7. De Caterina R., Husted S., Wallentin L., et al. European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost: 2013; 109 4 569 579
8. Husted S., de Caterina R., Andreotti F., et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost: 2014; 111 5 781 782
9. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
10. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
11. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
12. Giugliano R. P., Ruff C. T., Braunwald E., et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2013; 369 22 2093 2104
13. Skjoth F., Larsen T. B., Rasmussen L. H., Lip G. Y. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost: 2014; 111 5 981 988
14. Verdecchia P., Angeli F., Lip G. Y., Reboldi G. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. PLoS One: 2014; 9 6 e100478
15. Skjoth F., Larsen T. B., Rasmussen L. H. Indirect comparison studies-are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thromb Haemost: 2012; 108 3 405 406
16. Harenberg J., Marx S., Wehling M. Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next? Thromb Haemost: 2012; 108 3 407 409
17. Camm A. J., Lip G. Y., De Caterina R., et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J: 2012; 33 21 2719 2747
18. Ogawa S., Aonuma K., Tse H. F., et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythmia: 2013; 29 3 190 200
19. January C. T., Wann L. S., Alpert J. S., et al. AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol: 2014; 64 21 2246 2280
20. National Institute for Health and Clinical Excellence(NICE) NICE CG(180), Atrial Fibrillation(Update): The management of atrial fibrillation 2014. http://guidanceniceorguk/CG180. Accessed August 18, 2014
21. Skanes A. C., Healey J. S., Cairns J. A., et al. Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol: 2012; 28 2 125 136
22. JCS Joint Working Group Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). http://www.j-circ.or.jp/guideline/pdf/JCS2013-inoue-h.pdf. Accessed August 18, 2014
23. Olesen J. B., Fauchier L., Lane D. A., Taillandier S., Lip G. Y. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest: 2012; 141 1 147 153
24. Banerjee A., Lane D. A., Torp-Pedersen C., Lip G. Y. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost: 2012; 107 3 584 589
25. Pisters R., Lane D. A., Nieuwlaat R., de Vos C. B., Crijns H. J., Lip G. Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest: 2010; 138 5 1093 1100
26. Olesen J. B., Lip G. Y., Kamper A. L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med: 2012; 367 7 625 635
27. Kubitza D., Becka M., Mueck W., et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol: 2010; 70 5 703 712
28. Hohnloser S. H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J: 2012; 33 22 2821 2830
29. Fox K. A., Piccini J. P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J: 2011; 32 19 2387 2394
30. DiMatteo M. R., Giordani P. J., Lepper H. S., Croghan T. W. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care: 2002; 40 9 794 811
31. Zolfaghari S., Harenberg J., Froelich L., Wehling M., Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost: 2014; 40 1 121 128
32. Lane D. A., Lip G. Y. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost: 2014; 111 3 381 383
33. Lahaye S., Regpala S., Lacombe S., et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost: 2014; 111 3 465 473
34. 2 score. Chest: 2013; 144 5 1555 1563
35. 2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest: 2014; 146 3 719 726
36. Poli D., Antonucci E., Testa S., Lip G. Y. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med: 2014; 9 4 443 447